Highest-materiality recent filing
IN8bio Q1 2026 net loss $5.1M; GBM mPFS improved 97% vs SOC; cash $21.9M
Net loss of $5.1M ($0.26/sh) vs $5.6M ($2.16/sh) in Q1 2025; cash $21.9M up from $11.9M.
IN8bio reports FY2025 net loss $19.4M; GBM trial shows 97% PFS improvement
Net loss $19.4M ($4.44/share) vs $30.4M ($17.05/share) prior year; cash $27.1M vs $11.1M year-end 2024.
Initial closing: 5,127,029 shares at $1.38 and 9,452,677 pre-funded warrants for ~$20.1M gross.
IN8bio presents GBM trial data: mPFS 13.0 mo vs 6.6 SOC; mOS not reached at 16.4+ mo
Phase 1 INB-200 and Phase 2 INB-400 data presented at SNO 2025 for newly diagnosed glioblastoma.
IN8bio Q3 net loss $3.9M ($0.85/share); cash $10.7M; INB-619/100 updates
Net loss of $3.9M in Q3 2025 vs $7.1M in Q3 2024; basic and diluted EPS -$0.85 vs -$4.49.
INB-619 achieved complete B cell depletion in SLE donor models, equivalent to FDA-approved blinatumomab and mosunetuzumab.
IN8bio reports Q2 net loss of $5.1M; 4-year PFS milestone in glioblastoma trial
Net loss $5.1M ($1.24/sh) vs $8.6M ($5.51/sh) in Q2 2024; R&D expenses down to $2.5M from $5.2M.
IN8bio Phase 1 INB-200 shows mPFS 16.1 months, more than double SOC in GBM
Median PFS in repeated-dose patients reached 16.1 months vs 6.9 months historical SOC Stupp protocol.
IN8bio shareholders approve reverse stock split; all director nominees elected
Reverse stock split proposal approved with 43.6M votes for, 3.2M against, 90k abstain.
IN8bio reports Q1 2025 net loss of $5.6M; INB-100 shows 100% AML relapse-free at 20.1 months
Net loss $5.6M ($0.07/sh) vs. $8.6M ($0.20/sh) prior year; cash $11.9M as of March 31, 2025.
Warrant exercises for 7,178,934 Series A and 2,142,147 Series B shares at $0.1844 (insiders) or $0.1784 (others) per share.
IN8bio Announces Preclinical Data from Gamma-Delta T Cell Engager Platform at AACR 2025
INB-619 (CD19) and INB-633 (CD33) showed potent dose-related killing of leukemia cells at low picomolar concentrations in preclinical studies.
IN8bio reports Q4 2024 net loss $6.2M; cash $11.1M as of Dec 31; clinical updates on INB-100/200/400
Net loss Q4 2024 $6.2M ($0.08/share) vs $7.6M ($0.22/share) in Q4 2023; full-year net loss $30.4M vs $30.0M.
IN8bio unveils gamma-delta T cell engager platform with lead candidate INB-619
INB-600 platform expands both Vd1+ and Vd2+ T cells; lead INB-619 targets CD19 for B-cell cancers and autoimmune diseases.
IN8bio Phase 1 INB-100: 100% AML remission at median 20.1 months, 100% 1-year PFS/OS
All 9 AML patients remain in complete remission; median follow-up 20.1 months, longest >3 years.
IN8bio receives Nasdaq bid-price extension to Aug 4, 2025; stock moves to Capital Market
Nasdaq granted IN8bio until Aug 4, 2025 to achieve $1.00 closing bid for 10 consecutive days.
IN8bio reports 100% AML CR rate with INB-100 at ASH; no relapses after median 19.7 months
100% of AML patients (n=10) remain in complete remission after median 19.7 months follow-up; no relapses or new deaths as of Sept 30, 2024.
IN8bio Phase 1 INB-200 data: 50% of multi-dose patients alive beyond expected median OS
50% of multi-dose patients (n=10) alive beyond expected median OS from Stupp regimen; none in single-dose group (n=3).
IN8bio Q3 net loss $7.1M; cash $4.0M; closes $11.6M placement; INB-100/200 updates
Net loss of $7.1M ($0.15 per share) vs $7.2M loss ($0.23) in Q3 2023.
IN8bio raises $12.4M in private placement; amends Series A warrants
Gross proceeds of ~$12.4M from sale of units at $0.3950 per unit; closing expected Oct 4, 2024.
IN8bio cuts CEO Ho's salary to $544,680; other execs also reduced, severance enhanced
CEO William Ho salary cut from $612,000 to $544,680; Trishna Goswami from $495,000 to $440,550 effective Sept 1, 2024.
IN8bio cuts workforce 49%, suspends GBM trial to focus on AML therapy INB-100
Workforce reduced from 37 to 19 FTEs; exec/board take 11% cash compensation cut.
IN8bio reports 100% AML remission with INB-100; FDA guidance for registrational trial
100% of AML patients in Phase 1 trial remain in complete remission; all relapse-free beyond one year.
IN8bio receives Nasdaq minimum bid price deficiency notice; Q2 net loss $8.6M, cash $10.2M
Nasdaq notified IN8bio on Aug 6, 2024 that bid price closed below $1.00 for 31 consecutive days; 180-day compliance period to Feb 3, 2025.
IN8bio Phase 1 INB-100 shows 100% durable CR at 1 year in leukemia patients
100% of evaluable leukemia patients (n=10) remain in durable CR at 1 year as of May 31, 2024.
IN8bio reports 92% of INB-200 patients exceed 7-month PFS in Phase 1 GBM study
92% of evaluable patients exceeded median PFS of 7 months (Stupp regimen); median follow-up 11.7 months.
IN8bio reports 100% of evaluable patients in Phase 1 INB-100 trial remain in complete remission
All 10 evaluable patients alive, progression-free, and in durable CR as of Nov 3, 2023; 6 relapse-free for over 1 year.
IN8bio raises $14.4M in private placement; potential total up to $46.9M via warrant exercises
Initial gross proceeds of $14.4M from selling 11.8M units at $1.22/unit; extends cash runway into 2025.
All ten patients who completed mandated doses exceeded progression-free survival (PFS) of 7 months, exceeding standard-of-care median PFS of 4-7 months.
IN8bio starts Phase 2 GBM trial (INB-400) and completes Phase 1 dose escalation (INB-100)
Enrollment open for Phase 2 trial of INB-400 in newly diagnosed GBM; plans ~40 patients in Arm A; primary endpoint 12-month OS.
IN8bio reports Q2 2023 net loss of $7.7M, cash $17.0M; positive INB-200 Phase 1 data
Net loss $7.7M ($0.27/sh) vs $7.2M ($0.38/sh) in Q2 2022; R&D expense $4.1M, G&A $3.6M.
IN8bio Phase 1 INB-200 data shows 100% of GBM patients exceed historical median PFS
100% (8/8) patients exceeded historical median PFS of 4-7 months; two patients from three-dose cohort remain progression-free at 23.5 and 19.4 months.
Data presented at ASGCT 2023 demonstrate DeltEx T cells target and kill ovarian cancer cells even in platinum-resistant lines.
IN8bio Q1 net loss $7.5M, cash $10.9M; INB-100 achieves 100% CR in leukemia trial
Q1 net loss $7.5M ($0.30/sh); cash $10.9M at Mar 31; raised $9.9M via ATM after quarter end.
IN8bio reports 100% complete remission in INB-100 Phase 1 leukemia trial; RP2D selected
100% of evaluable patients (n=7) in durable CR; one patient progression-free beyond 3 years.
IN8bio reports FY2022 net loss $28.5M; cash $18.2M; clinical data positive
Cash $18.2M at Dec 31, 2022, down from $37.0M a year earlier; R&D spend $14.1M (FY2022) vs $7.3M.
On March 4, 2025, Travis Whitfill notified the Board of Directors (the “Board”) of IN8bio, Inc. (the “Company”) of his resignation from the Board and its committees, effective as of May 9, 2025.
On September 8, 2024, IN8bio, Inc. (the “Company”) and Trishna Goswami, M.D., the Company’s Chief Medical Officer, reached the mutual decision to have Dr. Goswami step down as Chief Medical Officer, effective September 6, 2024.
appointed Corinne Epperly, M.D., as a Class II director of the Company
appointed Jeremy Graff, Ph.D., as a Class I director of the Company
announced that the Board of Directors had appointed Kate Rochlin, Ph.D. as the Company’s Chief Operating Officer, effective as of December 1, 2021.
Effective as of November 15, 2021, IN8bio, Inc. (the “ Company ”) appointed Dr. Trishna Goswami as the Company’s Chief Medical Officer.
Max materiality 0.85 · Median 0.65 · Most common event other_material